Clinical Trials Logo

Carcinoma, Small Cell Lung clinical trials

View clinical trials related to Carcinoma, Small Cell Lung.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05566041 Recruiting - Clinical trials for Carcinoma, Small Cell Lung

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

REPLATINUM
Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.

NCT ID: NCT04253145 Recruiting - Clinical trials for Carcinoma, Small Cell Lung

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Start date: December 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, open-label, uncontrolled and multicenter phase I-II study in SCLC patients with ECOG PS 0-1 who have failed one prior platinum-containing line but no more than one chemotherapy-containing line. The study will be divided into two parts: a dose-ranging phase I with escalating doses of PM01183 in combination with a fixed dose of atezolizumab, followed by a single-arm phase II part with expansion at the RD determined during the phase I.

NCT ID: NCT02736916 Recruiting - Clinical trials for Carcinoma, Small Cell Lung

HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer

Start date: March 2016
Phase: N/A
Study type: Interventional

Prophylactic cranial irradiation (PCI) is an important treatment modality of patients with limited stage small cell lung cancer (LD-SCLC). However, PCI is also associated with several side effects, such as decline in memory and other cognitive functions. This provides the rationale to explore the clinical feasibility of hippocampal avoidance during WBRT. Previous studies have demonstrated the dosimetric capabilities of IMRT to conformally avoid the hippocampus without detriment to the radiation dose the remaining brain receives. The aims of this study is to evaluate the therapy efficacy and the safety profile of hippocampal-sparing whole-brain radiation therapy (HS-WBRT) for PCI in patients with LD-SCLC.